Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported strong FY25 results with revenue from operations rising about 29% to Rs. 268.72 crore (from Rs. 208.70 crore in FY24) and net profit jumping roughly 146% to Rs. 55.36 crore (from Rs. 22.46 crore). Q4 FY25 revenue stood at Rs. 58.56 crore with net profit of Rs. 6.58 crore, up about 85% year-on-year. The board recommended a final dividend of Rs. 2.5 per share (125%) on the new Rs. 2 face value, and appointed S S Kothari Mehta & Co as Internal Auditor for FY26. The company acquired Yash Pharma's India and Bhutan business for Rs. 94.01 crore in June 2024, sold its Faridabad factory for Rs. 41 crore booking a Rs. 23.36 crore exceptional gain, and executed a stock split from Rs. 5 to Rs. 2 face value effective January 8, 2025. Statutory auditor Walker Chandiok & Co LLP issued an unmodified (clean) opinion. A pending customs duty demand of Rs. 5.10 crore plus equal penalty was confirmed by authorities, which the company intends to appeal.
Strong top-line growth, a near-doubling of profit, and a 125% dividend are positive signals for shareholders, though part of the profit boost came from the one-time Faridabad factory sale. The clean audit report and the Yash Pharma acquisition expanding the dermatology and childcare portfolio are supportive, while the customs duty order remains a watch item that could weigh on sentiment if the appeal fails.